Screening for latent infection with Mycobacterium tuberculosis: A plea for targeted testing in low endemic regions

Expert Review of Molecular Diagnostics

Volumn 12, Issue 3, 2012, Pages 231-234

  Goletti, Delia ^a   Sester, Martina ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

accuracy; battey skin test; discordance; IGRA; latent tuberculosis infection; military recruits; NTM; QuantiFERON TB gold in tube test; T SPOT .TB test; targeted testing; TST

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DISEASE COURSE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM TUBERCULOSIS; NOTE; QUESTIONNAIRE; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION;

EID: 84859406141     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.14     Document Type: Note

References (19)

1. Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 33, 956-973 (2009). State-of-the-art consensus document summarizing current evidence on the microbiological and clinical status of latent infection with Mycobacterium tuberculosis, including its diagnosis.
2. Andrews JR, Noubary F, Walensky RP et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54(6), 784-791 (2012). Interesting estimation of the difference in disease progression in exposed individuals with or without prior contact with M. tuberculosis, which may in part explain the low positive predictive value of immune-based assays for latent infection.
3. Mancuso JD, Mazurek GH, Tribble D et al. Discordance among commercially-available diagnostics for latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 185(4), 427-434 (2012).
4. Sester M, Sotgiu G, Lange C et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37, 100-111 (2011). First meta-analysis that has assessed the potential of tuberculin skin testing and IFN-γ-release assays (IGRAs) to discriminate active tuberculosis from latent infection with M. tuberculosis.
5. Palazzo R, Spensieri F, Massari M et al. Use of whole-blood samples in in-house bulk and single-cell antigen-specific γ interferon assays for surveillance of Mycobacterium tuberculosis infections. Clin. Vaccin. Immunol. 15, 327-337 (2008).
6. Butera O, Chiacchio T, Carrara S et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect. Dis. 9, 182 (2009).
7. Pai M, Kalantri S, Menzies D. Discordance between tuberculin skin test and interferon-g assays. Int. J. Tuberc. Lung Dis. 10, 942-943 (2006).
8. Gallant CJ, Cobat A, Simkin L et al. Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest 137, 1071-1077 (2010).
9. Mancuso JD, Tribble D, Mazurek GH et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin. Infect. Dis. 53, 234-244 (2011). Analyzed the potential of tuberculosis risk assessment in predicting a positive tuberculin skin test or IGRA result. Together with [3], this provides strong evidence for the use of targeted testing to reduce unnecessary testing and treatment.
10. Weir RE, Gorak-Stolinska P, Floyd S et al. Persistence of the immune response induced by BCG vaccination. BMC Infect. Dis. 8, 9 (2008).
11. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, S221-S247 (2000).
12. Mazurek GH, Jereb J, Vernon A et al. Updated guidelines for using interferon-g release assays to detect Mycobacterium tuberculosis infection - United States. MMWR Recomm. Rep. 59, 1-25 (2010).
13. Erkens CG, Kamphorst M, Abubakar I et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur. Respir. J. 36, 925-949 (2010). Provides evidence-based consensus recommendations on contact tracing in low tuberculosis prevalence regions.
14. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-{g} release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 183, 88-95 (2011). The largest study demonstrating a higher positive predictive value for progression towards active tuberculosis for IGRA compared with tuberculin skin testing in the setting of contact tracing in a low endemic region.
15. Goletti D, Butera O, Vanini V et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur. Respir. J. 36, 135-142 (2010).
16. Delogu G, Chiacchio T, Vanini V et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS ONE 6, e18315 (2011).
17. Goletti D, Raja A, Syed Ahamed Kabeer B et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS ONE 5, e12577 (2010).
18. Sester U, Fousse M, Dirks J et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS ONE 6, e17813 (2011).
19. Leyten EM, Arend SM, Prins C et al. Discrepancy between Mycobacterium tuberculosis-specific g interferon release assays using short and prolonged in vitro incubation. Clin. Vaccine Immunol. 14, 880-885 (2007).